FDA Approves Gene Therapy for Children with Sickle Cell Disease and Beta Thalassemia

FDA Extends Gene Therapy Access to Toddlers

The U.S. Food and Drug Administration has expanded the approved use of the gene therapy Casgevy (exagamglogene autotemcel) to include patients aged 2 years and older. Previously approved for patients aged 12 years and older, the treatment now serves younger children battling sickle cell disease or transfusion-dependent beta thalassemia.

Preventing Organ Damage Through Early Intervention

The decision to lower the age threshold is a race against time. By intervening earlier, clinicians aim to stop significant, permanent organ damage before it begins. Megha Kaushal, MD, MSc, acting deputy director of the Office of Therapeutic Products at the FDA’s Center for Biologics Evaluation and Research, notes that this approval offers a critical window for treatment. Addressing the genetic root of these diseases early may prevent the cumulative health decline caused by chronic vaso-occlusive crises and the long-term complications of frequent blood transfusions.

Efficacy Data in Pediatric Trials

The label expansion rests on ongoing phase 3 clinical trials, specifically the CLIMB-141 and CLIMB-151 studies. The results in younger cohorts are striking:

• Sickle Cell Disease: Out of 11 children aged 5 to 11, eight had evaluable efficacy data. Every one of those eight patients remained free from protocol-defined severe vaso-occlusive crises for 12 consecutive months within the two years following treatment.
• Transfusion-Dependent Beta Thalassemia: In a trial of 15 patients aged 5 to 12, nine provided evaluable data. Eight achieved transfusion independence for 12 consecutive months, with a median duration of independence reaching 20.1 months.

Safety Profiles and Clinical Risks

Despite the therapeutic potential, the treatment carries notable risks. Clinical trials identified febrile neutropenia and mucositis as the most frequent adverse reactions, while children with sickle cell disease also experienced decreased appetite. Formal warnings on the product label include neutrophil engraftment failure, delayed platelet engraftment, hypersensitivity reactions, and risks linked to off-target genome editing.

Clinical Hope for Younger Patients

For families, the approval marks a shift in the standard of care. Haydar Frangoul, MD, MS, medical director of HCA healthcare’s Sarah Cannon transplant and cellular therapy program at TriStar Centennial Children’s Hospital, says the approval offers renewed hope. According to Frangoul, providing access to this gene therapy earlier allows for treatment before years of cumulative damage from these life-shortening conditions take hold.

Quick Facts: Understanding Casgevy

Casgevy is now the first and only gene therapy available for use in patients as young as 2 years with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.